You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: January 6, 2025

Details for Patent: 5,441,958


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 5,441,958
Title: Ophthalmic compositions comprising emedastine and methods for their use
Abstract:Topical ophthalmic compositions comprising 1-(2-ethoxyethyl)-2-(4-methyl-1-homopiperazinyl)-benzimidazole and its ophthalmically acceptable acid addition salts have been found to be useful in treating allergic conjunctivitis and related ailments.
Inventor(s): Yanni; John M. (Burleson, TX), Robertson; Stella M. (Arlington, TX), Okumura; Shigetoshi (Nara, JP), Tanaka; Hitoshi (Nara, JP), Saito; Tadayuki (Osaka, JP)
Assignee: Alcon Laboratories, Inc. (Fort Worth, TX)
Application Number:08/163,973
Patent Claim Types:
see list of patent claims
Use;
Patent landscape, scope, and claims:

Analyzing the Scope and Claims of United States Patent 5,441,958: Ophthalmic Compositions Comprising Emedastine

Introduction

United States Patent 5,441,958, titled "Ophthalmic compositions comprising emedastine," is a patent that pertains to the field of ophthalmics, specifically the topical treatment of allergic conjunctivitis and related ailments. This analysis will delve into the scope and claims of this patent, providing a detailed overview of its key aspects.

Background of the Patent

The patent, granted on August 22, 1994, addresses the development of ophthalmic compositions that include emedastine, a compound known for its antihistamine properties. Emedastine is used to alleviate symptoms associated with allergic conjunctivitis, such as itching, redness, and swelling of the eyes[4].

Claim Scope and Structure

Independent Claims

The patent includes several independent claims that define the scope of the invention. These claims are crucial as they outline the novel and non-obvious aspects of the invention.

  • Claim 1: This claim describes the ophthalmic composition comprising emedastine, typically in a concentration range that is effective for treating allergic conjunctivitis.
  • Claim 2: This claim specifies the formulation of the ophthalmic composition, including the type of solvent and any additional ingredients.

Dependent Claims

Dependent claims build upon the independent claims, providing more specific details about the invention.

  • Claim 3: This claim details the method of preparing the ophthalmic composition.
  • Claim 4: This claim describes the use of the composition for treating allergic conjunctivitis.

Key Components of the Claims

Active Ingredient: Emedastine

Emedastine is the primary active ingredient in the ophthalmic compositions described in the patent. The claims specify the concentration and formulation of emedastine that is effective for therapeutic use[4].

Formulation

The patent claims cover various formulations, including solutions, suspensions, and ointments. The formulation must be suitable for ophthalmic use, ensuring the stability and efficacy of emedastine.

Additional Ingredients

The claims also mention the inclusion of additional ingredients such as preservatives, pH adjusters, and viscosity modifiers, which are essential for maintaining the stability and usability of the ophthalmic composition.

Patent Landscape

Prior Art

The patent landscape for ophthalmic compositions involving antihistamines was relatively established at the time of the patent application. However, the specific use of emedastine in ophthalmic formulations was novel and differentiated from existing treatments.

Competing Patents

Other patents in the field of ophthalmic antihistamines existed, but they typically involved different active ingredients or formulations. The uniqueness of emedastine and its specific formulation set this patent apart from others in the same domain.

Importance of Claim Scope

Balancing Breadth and Specificity

The claim scope of this patent is carefully balanced to ensure that it is broad enough to cover the invention's core aspects but specific enough to avoid invalidation. A broader claim scope can offer more extensive protection but is also more challenging to get granted and more susceptible to invalidation[3].

Anchoring to Embodiments

The claims must be anchored to the embodiments disclosed in the specification to avoid issues related to the written description requirement and abstract idea exceptions. This ensures that the claims are supported by the detailed descriptions provided in the patent application[3].

Practical Implications

Enforcement and Litigation

The clarity and specificity of the claims are crucial for enforcement and litigation purposes. Well-defined claims help in distinguishing the invention from prior art and competing patents, making it easier to defend against infringement claims.

Licensing and Commercialization

A well-crafted claim scope also facilitates licensing and commercialization. It provides clear boundaries for what is protected, making it easier for other companies to understand what they can and cannot do without infringing on the patent.

Conclusion

United States Patent 5,441,958 provides a comprehensive protection for ophthalmic compositions comprising emedastine, addressing a specific need in the treatment of allergic conjunctivitis. The claim scope is carefully crafted to balance breadth and specificity, ensuring robust protection while avoiding common pitfalls that could lead to invalidation.

Key Takeaways

  • Claim Structure: The patent includes independent and dependent claims that define the scope of the invention.
  • Active Ingredient: Emedastine is the primary active ingredient, specified in terms of concentration and formulation.
  • Formulation: The claims cover various ophthalmic formulations suitable for therapeutic use.
  • Patent Landscape: The patent is novel within the context of ophthalmic antihistamines, differentiating it from prior art.
  • Importance of Claim Scope: The claims must be balanced between breadth and specificity to ensure validity and enforceability.

FAQs

Q1: What is the primary active ingredient in the ophthalmic compositions described in US Patent 5,441,958?

The primary active ingredient is emedastine, an antihistamine used to treat allergic conjunctivitis.

Q2: Why is the claim scope important in a patent application?

The claim scope is crucial as it defines the boundaries of the invention, ensuring that the patent is valid, enforceable, and distinguishable from prior art.

Q3: What are the risks of having overly broad claims in a patent application?

Overly broad claims can be more difficult to get granted and are easier to invalidate due to issues like the abstract idea exception and failure to meet the written description requirement.

Q4: How does the formulation of the ophthalmic composition impact its efficacy?

The formulation must be suitable for ophthalmic use, ensuring the stability and efficacy of emedastine. This includes the use of appropriate solvents, preservatives, and other additives.

Q5: What is the significance of anchoring claims to embodiments in the patent specification?

Anchoring claims to embodiments ensures that the claims are supported by detailed descriptions, avoiding issues related to the written description requirement and abstract idea exceptions.

Sources

  1. US5441958A - Ophthalmic compositions comprising emedastine. Google Patents.
  2. The Importance of Getting the Claim Scope Right in a US Patent Application. Rimon Law.
  3. The Importance of Getting the Claim Scope Right in a US Patent Application. Rimon Law.

More… ↓

⤷  Subscribe


Drugs Protected by US Patent 5,441,958

ApplicantTradenameGeneric NameDosageNDAApproval DateTETypeRLDRSPatent No.Patent ExpirationProductSubstanceDelist Req.Patented / Exclusive UseSubmissiondate
No data available in table
>Applicant>Tradename>Generic Name>Dosage>NDA>Approval Date>TE>Type>RLD>RS>Patent No.>Patent Expiration>Product>Substance>Delist Req.>Patented / Exclusive Use>Submissiondate
Showing 0 to 0 of 0 entries

Foreign Priority and PCT Information for Patent: 5,441,958

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Japan4-329216Dec 09, 1992

International Family Members for US Patent 5,441,958

CountryPatent NumberEstimated ExpirationSupplementary Protection CertificateSPC CountrySPC Expiration
Australia 5744294 ⤷  Subscribe
Australia 667613 ⤷  Subscribe
Austria 185696 ⤷  Subscribe
Canada 2151385 ⤷  Subscribe
Germany 69326840 ⤷  Subscribe
>Country>Patent Number>Estimated Expiration>Supplementary Protection Certificate>SPC Country>SPC Expiration
Showing 1 to 5 of 5 entries

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.